defactinib (GSK2256098)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for defactinib (GSK2256098), covering 2026-04-07 to 2026-04-07. Get the full timeline:
Most recent: Clinical Trial Update: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas [Phase 2]